eJHaem (Feb 2023)

Outcomes after allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia patients with der(1;7)(q10;p10)

  • Hiroki Mizumaki,
  • Ken Ishiyama,
  • Jun Aoki,
  • Jinichi Mori,
  • Shohei Mizuno,
  • Noriko Doki,
  • Takahiro Fukuda,
  • Naoyuki Uchida,
  • Masahito Onizuka,
  • Masatsugu Tanaka,
  • Yuta Katayama,
  • Yukiyasu Ozawa,
  • Kazuhiro Ikegame,
  • Satoru Takada,
  • Toshiro Kawakita,
  • Nobuyuki Aotsuka,
  • Yoshiko Atsuta,
  • Masamitsu Yanada

DOI
https://doi.org/10.1002/jha2.609
Journal volume & issue
Vol. 4, no. 1
pp. 251 – 257

Abstract

Read online

Abstract The prognosis of acute myeloid leukemia (AML) patients with der(1;7)(q10;p10) who underwent allogeneic hematopoietic stem cell transplantation (allo‐SCT) is unclear due to its rarity. We retrospectively analyzed 151 AML patients with der(1;7)(q10;p10) and compared the findings with those of 853 AML patients with monosomy 7 or chromosome 7q deletion (‐7/del(7q)) using Japanese nationwide registry data. The der(1;7)(q10;p10) group showed significantly better transplant outcomes than the ‐7/del(7q) group. In the multivariate analysis of the der(1;7)(q10;p10) group, additional chromosomal abnormalities and a poor performance status significantly influenced the survival. In conclusion, allo‐SCT is a feasible treatment option for AML patients with der(1;7)(q10;p10).

Keywords